Physician profile
Muhammad Suhail
NPI 1679598387
$731.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $91.98 · 2021: $12.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $190.99 | 2019-2020 | |
| Abbvie INC. | $162.06 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.16 | 2019-2020 | |
| Novo Nordisk INC | $56.40 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $45.05 | 2019 | |
| Shire North American Group INC | $32.83 | 2019 | |
| Valeritas, INC. | $22.41 | 2019 | |
| Corcept Therapeutics | $21.55 | 2019 | |
| Horizon Therapeutics Plc | $21.35 | 2019 | |
| Antares Pharma, INC. | $12.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Suhail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.